Avalo Therapeutics (AVTX) Consolidated Net Income (2014 - 2026)
Avalo Therapeutics posted quarterly Consolidated Net Income of -$19.6 million for Q1 2026, down 49.29% year-on-year from -$38.7 million in Q1 2025, and down 43.08% on a QoQ basis from -$13.7 million in Q4 2025.
Avalo Therapeutics (AVTX) has 12 years of Consolidated Net Income data on file, last reported at -$19.6 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income fell 49.29% year-over-year to -$19.6 million; the trailing twelve-month figure through Mar 2026 stood at -$84.7 million (down 216.06% YoY), and the FY2025 full-year result was -$78.3 million, down 122.78% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$19.6 million, down from -$13.7 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $98.5 million in Q2 2024 and bottomed at -$121.3 million in Q1 2024.
- The 4-year median for Consolidated Net Income is -$13.1 million (2025), against an average of -$12.7 million.
- Peak annual rise in Consolidated Net Income reached 1301.79% in 2024, while the deepest fall reached 1118.38% in 2024.
- A 4-year view of Consolidated Net Income shows it stood at -$8.2 million in 2023, then plunged by 332.65% to -$35.3 million in 2024, then soared by 61.18% to -$13.7 million in 2025, then tumbled by 43.08% to -$19.6 million in 2026.
- The last three Consolidated Net Income figures came in at -$19.6 million (Q1 2026), -$13.7 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | -19.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.63 Mn |
| Dec 31, 2025 | -13.72 Mn |
| Sep 30, 2025 | -30.63 Mn |
| Jun 30, 2025 | -20.77 Mn |
| Mar 31, 2025 | -13.15 Mn |
| Dec 31, 2024 | -35.34 Mn |
| Sep 30, 2024 | 23.04 Mn |
| Jun 30, 2024 | 98.46 Mn |
| Mar 31, 2024 | -121.29 Mn |
| Dec 31, 2023 | -8.17 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -8.19 Mn |
| Mar 31, 2023 | -9.96 Mn |
| Dec 31, 2021 | -65,000.00 |
| Sep 30, 2021 | 76,000.00 |
| Jun 30, 2021 | 69,000.00 |
| Mar 31, 2021 | -106,000.00 |
| Dec 31, 2020 | 499,000.00 |
| Sep 30, 2020 | -198,000.00 |
| Jun 30, 2020 | -455,000.00 |
| Mar 31, 2020 | 1.04 Mn |
| Dec 31, 2019 | 7.25 Mn |
| Sep 30, 2019 | -1.09 Mn |
| Jun 30, 2019 | -3.68 Mn |
| Mar 31, 2019 | -2.29 Mn |
| Dec 31, 2018 | -780,204.00 |
| Sep 30, 2018 | -24.60 Mn |
| Jun 30, 2018 | -6.01 Mn |
| Mar 31, 2018 | -3.88 Mn |
| Dec 31, 2017 | -3.09 Mn |
| Sep 30, 2017 | 18.72 Mn |
| Jun 30, 2017 | -1.80 Mn |
| Mar 31, 2017 | -1.96 Mn |
| Dec 31, 2016 | -1.64 Mn |
| Sep 30, 2016 | -6.17 Mn |
| Jun 30, 2016 | -3.62 Mn |
| Mar 31, 2016 | -5.09 Mn |
| Dec 31, 2015 | -3.83 Mn |
| Sep 30, 2015 | -2.35 Mn |
| Jun 30, 2015 | -3.11 Mn |
| Mar 31, 2015 | -2.70 Mn |
| Dec 31, 2014 | -4.05 Mn |
| Sep 30, 2014 | -6.38 Mn |